🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Jefferies Group’s URGN Holdings & Trades

First Buy
Q1 2024
Duration Held
8 Quarters
Largest Add
Q2 2025
+1.38 M Shares
Current Position
2.2 M Shares
$51.52 M Value

Jefferies Group's URGN Position Overview

Jefferies Group (via Jefferies Financial Group Inc.) currently holds 2.2 M shares of UroGen Pharma Ltd. (URGN) worth $51.52 M, representing 0.26% of the portfolio. First purchased in 2024-Q1, this short-term holding has been held for 8 quarters.

Based on 13F filings, Jefferies Group has maintained this position in URGN for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 1.38 M shares. Largest reduction occurred in Q1 2025, reducing 150,929 shares.

Analysis based on 13F filings available since 2013 Q2

Jefferies Group's UroGen Pharma (URGN) Holding Value Over Time

Track share changes against reported price movement

Quarterly UroGen Pharma (URGN) Trades by Jefferies Group

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2025 +1.38 M Add 169.90% 2.2 M $13.70
Q1 2025 -150,929 Reduce 15.63% 815,000 $11.06
Q4 2024 +929 Add 0.10% 965,929 $10.65
Q2 2024 +125,000 Add 14.88% 965,000 $16.78
Q1 2024 +840,000 New Buy 840,000 $15.00

Jefferies Group's UroGen Pharma Investment FAQs

Jefferies Group first purchased UroGen Pharma Ltd. (URGN) in Q1 2024, acquiring 840,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jefferies Group has held UroGen Pharma Ltd. (URGN) for 8 quarters since Q1 2024.

Jefferies Group's largest addition to UroGen Pharma Ltd. (URGN) was in Q2 2025, adding 2,199,652 shares worth $30.14 M.

According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 2,199,652 shares of UroGen Pharma Ltd. (URGN), valued at approximately $51.52 M.

As of the Q4 2025 filing, UroGen Pharma Ltd. (URGN) represents approximately 0.26% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.

Jefferies Group's peak holding in UroGen Pharma Ltd. (URGN) was 2,199,652 shares, as reported at the end of Q2 2025.